Танзанія - англійська - Tanzania Medicinces & Medical Devices Authority

remedica ltd, cyprus - piroxicam - capsules - 20 mg

Танзанія - англійська - Tanzania Medicinces & Medical Devices Authority

remedica ltd, cyprus - meloxicam - tablets - 7.5

Танзанія - англійська - Tanzania Medicinces & Medical Devices Authority

remedica ltd, cyprus - meloxicam - tablets - 15

Танзанія - англійська - Tanzania Medicinces & Medical Devices Authority

remedica ltd, cyprus - carbamazepine - tablets - 200

Мальта - англійська - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - hyoscine butylbromide - coated tablet - hyoscine butylbromide 10 mg - drugs for functional gastrointestinal disorders

Вірменія - англійська - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

remedica ltd - risperidone - tablets film-coated - 2mg (60/6x10/) in blister

Мальта - англійська - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - propranolol hydrochloride - film-coated tablet - propranolol hydrochloride 10 mg - beta blocking agents

Ізраїль - англійська - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib hydrochloride - film coated tablets - erlotinib hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Ізраїль - англійська - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Ізраїль - англійська - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib hydrochloride - film coated tablets - erlotinib hydrochloride 25 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib s.k. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib s.k. is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib s.k. is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib s.k. is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.